Patients were excluded from the trial if they were harboring EGFR mutations or ALK translocations, had an Eastern Cooperative Oncology Group (ECOG) performance status ≥2, had untreated brain metastasis, or were receiving any dose of oral steroids for an autoimmune disease. The gene discussed is EGFR; the disease is autoimmune disease.